Trailing-twelve-month (TTM) revenue is $16.84 Billion with a year-over-year growth of +7.11%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $4,165,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-30 |
| Q4 FY2025Period ended 2025-12-31 | $4,196,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-23 |
| Q1 FY2026Period ended 2026-03-31 | $4,066,100,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-07 |
| Q2 FY2026Period ended 2026-06-30 | $4,415,400,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-06 |
| TTM revenue | $16,842,500,000 |
Current P/S: $77,727,546,840 market capitalization ÷ $16,842,500,000 TTM revenue = 4.61x.
Market capitalization source: FMP quote. Quote observed 2026-09-11T20:00:02.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $4.42B.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-09-13T22:42:10.271Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-11.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Global Healthcare and Life Sciences | N/A | $1.2B | $1.6B | $1.6B | $1.4B | N/A |
| Global Industrial | $6.0B | $6.3B |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|
| Asia Pacific | $1.2B | $1.3B | $1.3B | $1.4B |
| C [N] | $684M | $670M | $697M | $722M |
| Canada | $416M | $453M | $479M | $499M |
$16.84B
$16.84 Billion
+7.11%
vs. $15.72B a year ago (TTM)
+6.78%
5 Year compound annual growth rate
1 Year
+7.11%
3 Year
+4.49%
5 Year
+6.78%
10 Year
+2.41%
15 Year
+6.71%
20 Year
+6.64%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $16.08B | +$339.80M | +2.16% |
| 2024 | $15.74B | +$421.20M | +2.75% |
| 2023 | $15.32B | +$1.13B | +7.98% |
| 2022 | $14.19B | +$1.45B | +11.42% |
| 2021 | $12.73B | +$942.90M | +8.00% |
| 2020 |
TTM Growth
+7.11%
3-Year CAGR
+4.49%
5-Year CAGR
+6.78%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-09-13T22:42:10.271Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-11.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $7.2B |
| $7.9B |
| N/A |
| Global Institutional | $3.6B | N/A | N/A | N/A | N/A | N/A |
|---|
| Global Institutional and Specialty | N/A | $4.0B | $4.5B | $5.0B | $5.4B | $6.1B |
|---|
| Global Life Sciences | N/A | N/A | N/A | N/A | N/A | $748M |
|---|
| Global Pest Elimination | N/A | N/A | N/A | N/A | $1.2B | $1.2B |
|---|
| Global Water | N/A | N/A | N/A | N/A | N/A | $8.0B |
|---|
| Other | $1.1B | $1.2B | $1.4B | $1.4B | N/A | N/A |
|---|
| Europe |
|---|
| $3.0B |
| $3.2B |
| $3.2B |
| $3.3B |
| Latin America | $861M | $1.0B | $1.1B | $1.1B |
|---|
| Middle East And Africa | $509M | $553M | $625M | $638M |
|---|
| UNITED STATES | $7.4B | $8.1B | $8.3B | $8.5B |
|---|
| $11.79B |
| ($771.80M) |
| (6.14%) |
| 2019 | $12.56B | ($2.11B) | (14.36%) |
| 2018 | $14.67B | +$832.30M | +6.02% |
| 2017 | $13.84B | +$683.10M | +5.19% |
| 2016 | $13.15B | ($392.30M) | (2.90%) |
